within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01A_AntiinflammatoryAndAntirheumaticProductsNonStero.M01AA03_Oxyphenbutazone;

model Oxyphenbutazone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 1.1111111111111112e-07,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.0087,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008333333333333333,
    Tlag = 600,
    Vdp = 0.0031,
    k12 = 1.1388888888888888e-07,
    k21 = 1.1388888888888888e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Oxyphenbutazone</td></tr><tr><td>ATC code:</td><td>M01AA03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>8.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) of the pyrazolidinedione class, formerly used in the treatment of rheumatoid arthritis and other inflammatory conditions. Due to safety concerns, particularly risk of severe adverse hematological reactions such as agranulocytosis, the drug is no longer approved or widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for healthy adult volunteers (sex not specified) following oral administration.</p><h4>References</h4><ol><li><p>Chay, S, et al., &amp; Yocum, J (1984). Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. <i>Journal of veterinary pharmacology and therapeutics</i> 7(4) 265–276. DOI:<a href=\"https://doi.org/10.1111/j.1365-2885.1984.tb00911.x\">10.1111/j.1365-2885.1984.tb00911.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6512917/\">https://pubmed.ncbi.nlm.nih.gov/6512917</a></p></li><li><p>Brouwers, JR, &amp; de Smet, PA (1994). Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. <i>Clinical pharmacokinetics</i> 27(6) 462–485. DOI:<a href=\"https://doi.org/10.2165/00003088-199427060-00005\">10.2165/00003088-199427060-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7882636/\">https://pubmed.ncbi.nlm.nih.gov/7882636</a></p></li><li><p>Tobin, T, et al., &amp; Lees, P (1986). Phenylbutazone in the horse: a review. <i>Journal of veterinary pharmacology and therapeutics</i> 9(1) 1–25. DOI:<a href=\"https://doi.org/10.1111/j.1365-2885.1986.tb00008.x\">10.1111/j.1365-2885.1986.tb00008.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3517382/\">https://pubmed.ncbi.nlm.nih.gov/3517382</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M01AA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Oxyphenbutazone;
